ArticleMaterials today. Bio2026
Injectable anti-inflammatory, antioxidant supramolecular nanofiber hydrogel for peripheral nerve injury repair and neuropathic pain relief.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focusing on inflammation-driven pyroptosis in postherpetic neuralgia: from molecular mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with peripheral nerve injury (PNI) often experience neuropathic pain (NP), which is difficult to treat effectively due to ongoing inflammation and oxidative stress that impede nerve repair. Traditional anti-inflammatory antioxidants are limited by short half-lives and significant side effects. This study introduces a supramolecular hydrogel formed by combining anti-inflammatory betamethasone phosphate (Betp) with calcium chloride to create betamethasone phosphate hydrogel (Betp@Gel). The antioxidant curcumin (Cur) was incorporated into this gel to form Cur/Betp@Gel, which can be injected directly at the injury site for sustained Cur release. Cur/Betp@Gel demonstrates superior sustained-release capabilities and therapeutic effectiveness compared to Betp@Gel or Cur alone. It enhances pain relief, supports functional recovery after nerve damage, and promotes nerve repair and regeneration. This is achieved by Betp@Gel's anti-inflammatory effects, which inhibit TNF-α, IL-1β, and IL-6, combined with Cur's continuous slow release, which scavenges reactive oxygen species (ROS). Additionally, Cur/Betp@Gel mitigates PNI-induced spinal inflammation by reducing GFAP and Iba-1 expression in the spinal cord. Overall, in-situ injection of Cur/Betp@Gel is a promising strategy for aiding nerve repair and alleviating neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.